Search

To observe the effect of Huangjing Zanyu Capsule (HZC) on sperm mitochondrial membrane potential (MMP) in asthenozoospermia patients.We assigned 70 asthenozoospermia patients to a treatment group (n = 39) and a control group (n = 31), the former treated with oral HZC at the dose of 4 capsules tid for 3 months while the latter left untreated. We obtained semen parameters from the patients and detected their sperm mitochondrial membrane potentials (MMP) by JC-1 staining and flow cytometry before and after medication, followed by comparison between the two groups.The total effectiveness rate was 71.05% in the treatment group and natural pregnancy was achieved in 3 cases during the medication. A total of 35 patients in the treatment group and 30 controls completed all the laboratory examinations after a 3-month observation. Compared with the controls, the patients treated with HZC exhibited significant improvement after medication in MMP (variation value: ［1.19 ± 10.36］% vs ［20.28 ± 14.21］%, P0.01), total sperm motility (variation value: ［3.46 ± 8.67］% vs ［20.68 ± 14.12］%, P0.01), the percentage of progressively motile sperm (variation value: ［2.26 ± 8.29］% vs ［17.58 ± 12.73］%, P0.01), and the percentage of morphologically normal sperm (variation value: ［0.23 ± 3.48］% vs ［3.37 ± 3.99］%, P0.01). MMP was significantly correlated with total sperm motility (r = 0.69, P0.01), progressive sperm motility (r = 0.75, P0.01) and normal sperm morphology (r = 0.26, P0.01).Huangjing Zanyu Capsule can enhance sperm mitochondrial membrane potential and sperm mitochondrial function, thus improving total sperm motility, progressive sperm motility and normal sperm morphology. It is safe and effective for the treatment of asthenospermia.目的： 观察黄精赞育胶囊对弱精子症患者精子线粒体膜电位的影响及临床疗效。 方法： 弱精子症患者70例分药物治疗组（n=39）和空白对照组(n=31)做队列观察研究。药物治疗组予黄精赞育胶囊口服3个月，1次4粒，每日3次。服用时可备孕，期间若配偶怀孕则停止用药。空白对照组不予药物干预。观察初次就诊和3个月后精液参数变化，及JC-1染色后流式细胞仪检测精子线粒体膜电位（MMP）值的变化。 结果： 两组各失随访1例。药物治疗组总有效率为71.05%，服药过程中3例患者女方自然妊娠。药物治疗组35例患者完成观察期结束后检查，MMP%、精子总活力、前向运动精子百分率（PR%）、精子形态均有改善，其变化值较空白对照组30例患者的测定值有显著差异（P0.01），分别为△MMP%: (20.28±14.21)% vs (1.19±10.36)%； △PR%: (17.58±12.73)% vs (2.26±8.29)%；△总活力: (20.68±14.12)% vs (3.46±8.67)%；△正常形态精子百分率: (3.37±3.99)% vs (0.23±3.48)%。MMP%与精子总活力（r=0.69）、PR%（r=0.75）、正常形态精子百分率（r=0.26）具有显著相关性(P0.01)。结论： 黄精赞育胶囊能提高精子MMP值，改善线粒体功能，从而有效增加精子活力及PR%并改善精子形态，对治疗弱精子症安全有效。.

To evaluate the clinical efficiency and safety of two-micron laser resection of the prostate-tangerine technique (TmLRP-TT) for the treatment of large-volume (70 ml) prostate in patients with benign prostatic hyperplasia (BPH).This retrospective analysis included 80 BPH patients with the prostatic volume larger than 70 ml, all treated by TmLRP-TT. We comparatively analyzed the levels of hemoglobin and serum sodium before and after surgery, recorded intra- and post-operative com- plications, and followed up the patients at 6 and 12 months after operation for International Prostate Symptom Score (IPSS), quality of life (QOL), maximum flow rate (Qmax), and postvoid residual urine volume (PVR).All the operations were successfully completed. The mean hemoglobin decreased (0.68 +/- 0.43) g/dl intraoperatively, but no apparent reduction was observed in serum sodium. Lower urinary tract symptoms were relieved significantly in all the cases. At 12 months after surgery, IPSS was decreased by 73.89% as compared with the baseline (20.03 +/- 6.9 vs 5.23 +/- 3.59), QOL by 64.55% (4.09 +/- 1.19 vs 1.45 +/- 1.36), and PVR by 79.30% (97.31 +/- 57.90 vs 20.14 +/- 24.20 ml), while Qmax increased by 140.42% ([8.04 +/- 3.62] vs [19.33 +/- 3.28] ml/s). The incidence of complications was low either intraoperatively or during the 12 months after operation.TmLRP-TT is a safe and effective surgical endoscopic approach to the treatment of large-volume prostate in BPH patients.

To study the different proportions of intermediate epithelial cells in human prostate cancer tissue and their clinical significance.We performed immunohistochemical staining for Cytokeratin 5 (CK5) and Cytokeratin 8 (CK8) on 60 samples of human prostate cancer, determined the proportions of intermediate epithelial cells in the cancer tissue, and classified the samples into 2 types, one with a majority of intermediate epithelial cells (CaP-INT, n = 32), and the other composed mostly of luminal epithelial cells (CaP-LUM, n = 28). Then we compared the 2 types of prostate cancer in the expression of the androgen receptor (AR), age of the patient, serum t-PSA, prostate volume, Gleason score, clinical stage, androgen resistance, and incidence of distant metastasis.CaP-INT showed a significantly lower expression of AR ([24.42 +/- 11.41] %) and a higher incidence of distant metastasis (n = 14) than CaP-LUM ([77.21 +/- 10.22] % and n = 4) (P0.05). In the CaP-INT group, 6 of the 26 endocrinologically treated cases developed into androgen-independent prostate cancer (AIPC), while in the CaP-LUM group, only 1 out of 23 (P0.05). The former also showed remarkably higher clinical stages than the latter (P0.05), but no significant differences were found in age, serum t-PSA, prostate volume and Gleason score between the two groups (P0.05).A higher proportion of intermediate epithelial cells may lead to increased invasiveness and metastasis of human prostate cancer.

To investigate targeted degradation of the androgen receptor (AR) by chimeric molecules (DHT-PROTAC) via the ubiquitin-proteasome pathway in androgen-independent prostate cancer CA-2B cells, and explore the proliferation, secretion and apoptosis of the treated cells.C4-2B cells were treated with DHT-PROTAC, and then the expressions of the AR protein and caspase3 in the C4-2B cells were detected by immunohistochemistry and Western blot. The concentration of PSA in the supernatant was examined by ELISA. The cells were counted and their proliferation analyzed by a growth curve. The inhibitory effect on the growth of C4-2B cells was evaluated by MIT assay.Compared with the control group, the DHT-PROTAC-treated group showed an obviously decreased expression of AR proteins with a significant attenuation of the band signals (P0.05), a 40% reduction of the AR-positive cells and a 60% decrease of the PSA concentration in the supernatant (P0.05). DHT-PROTAC exhibited an inhibitory effect on the C4-2B cells in a time-dependant manner (P0.05).The chimeric molecule (DHT-PROTAC) can target the degradation of androgen receptors, reduce the secretion of PSA and repress the in vitro growth of C4-2B cells.

To discuss the treatment of advanced cancer of abdominal cryptorchidism.The combined method, including preoperation chemotherapy + surgery + postoperation radiotherapy and chemotherapy, was used to treat 12 cases of the advanced cancer of abdominal cryptorchidism and the effects were evaluated.The patients recovered smoothly without complications of operation. The side effect of chemotherapy and radiotherapy was very slight. Eleven out of 12 cases were followed up. All 11 cases survived and had no recurrence.The results of combined method to treat advanced cancer of abdominal cryptorchidism is very perfect.